Lipid‐lowering therapy of everolimus‐related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). (21st July 2017)

• Record Type: Journal Article
• Authors: De Gennaro Colonna, V.; Pavanello, C.; Rusconi, F.; Sartore‐Bianchi, A.; Siena, S.; Castelnuovo, S.; Sirtori, C. R.; Mombelli, G.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 43:Number 1(2018)
• Page Start: 114
• Page End: 116
• Publication Date: 2017-07-21
• Subjects: everolimus -- fenofibrate -- hypertriglyceridaemia -- mammalian target of rapamycin inhibitors; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12588
• Languages: English
• ISSNs: 0269-4727

Abstract

Summary: What is known and objective: Hypertriglyceridaemia (HTG) is a potentially serious side effect of everolimus therapy. We here report a case of severe HTG in an everolimus‐treated patient and provide recommendations for its management. Case summary: The patient was a 70‐year‐old woman, being treated with everolimus for a pancreatic neuroendocrine tumour (pNET). She developed severe HTG to a maximum of 969 mg/dL after 22 months of therapy. Treatment with fenofibrate rapidly normalized triglyceride (TG) levels. What is new and conclusion: S evere HTG may occur in everolimus‐treated patients. Prescription of the appropriate therapy can allow patients to continue this medication. Abstract : Treatment with everolimus induces severe hypertriglyceridemia, possibly decreasing lipoprotein lipase (LPL) activity, reducing degradation of apolipoprotein B100 (apoB100) and upregulating the adipocyte fatty acid‐binding protein (aP2) expression. After treatment with fenofibrate 145 mg/day, triglycerides (TG) levels strikingly decrease by about 32%.